Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

3D011-08 from 3D Medicines was approved of conducting clinical trials

2021-02-08
|
Page View:

Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines has the capacity to develop innovative drugs with global intellectual property rights, which has laid a solid foundation for the achievement of the company’s long-term sustainable development strategic goals. 3D011 is a class I innovative drug for the treatment of advanced solid tumors.

Medicilon's preparation laboratory and workshop area is about 4,000 square meters, with 100 professional R&D teams, of which more than 40% are masters/doctors, and more than 95% are undergraduates. The team has rich experience in successful research and development of innovative drugs, consistency evaluation, and improved new drugs, and experience in China-US dual filing and project management. The Medicilon pharmaceutical preparation R&D team has successfully cooperated with well-known large and medium-sized pharmaceutical companies worldwide, and has accumulated 18 years of experience in the research and application of innovative drugs and generic drugs. We provide one-stop and systematic preparation R&D services covering innovative drugs and generic drugs to meet the needs of customers at different stages of R&D.

Related Articles

Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration

Share:
Return
Relevant newsRelevant news